# KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

> **NCT03925870** · PHASE2 · COMPLETED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 45 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** KN046

## Key facts

- **NCT ID:** NCT03925870
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-21
- **Primary completion:** 2021-08-26
- **Final completion:** 2022-07-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03925870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03925870, "KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03925870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*